Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

51.20 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

3 Reasons to Sell CORT and 1 Stock to Buy Instead

Today 0:00 EDT

Corcept’s stock price has taken a beating over the past six months, shedding 35% of its value and falling to $50.98 per share. This was partly driven by its ...

Via StockStory

3 High-Flying Stocks We Think Twice About

May 11, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

Corcept (CORT) Q1 2026 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q1 2026 Earnings Transcript

Via The Motley Fool

Corcept (CORT) Q4 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q4 2025 Earnings Transcript

Via The Motley Fool

Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗

April 30, 2026

Via Chartmill

Corcept (CORT) Q1 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q1 2025 Earnings Transcript

Via The Motley Fool

Corcept (CORT) Q2 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q2 2025 Earnings Transcript

Via The Motley Fool

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

May 04, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...

Via StockStory

Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation ↗

April 08, 2026

Via Chartmill

Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗

March 18, 2026

Via Chartmill

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

April 30, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...

Via StockStory

Corcept Earnings: What To Look For From CORT

April 28, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept m...

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore

April 21, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Via StockStory

Topics Economy

3 Overrated Stocks That Concern Us

April 16, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

April 10, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

2 Profitable Stocks to Consider Right Now and 1 We Avoid

April 06, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

2 Cash-Heavy Stocks Worth Your Attention and 1 We Find Risky

April 02, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Via StockStory

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

3 Reasons to Avoid CORT and 1 Stock to Buy Instead

March 30, 2026

Shareholders of Corcept would probably like to forget the past six months even happened. The stock dropped 56.3% and now trades at $36.31. This was partly dr...

Via StockStory

Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week ↗

March 27, 2026

It was a historic stretch of time for the biotech.

Via The Motley Fool

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Topics Economy Intellectual Property

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗

March 25, 2026

A top regulator approved one of its drugs that afternoon.

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

What's Behind The Jump In Corcept Therapeutics Stock? ↗

March 25, 2026

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary...

Via Benzinga

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 22, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid

March 11, 2026

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

Via StockStory

Topics Credit Cards

CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst ↗

February 25, 2026

The company guided for $900 million to $1 billion in 2026 revenue.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.